Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD
It looks like Lexicon Pharmaceuticals’ second bid to get US Food and Drug Administration (FDA) approval for Zynquista (sotagliflozin) will…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is reporter in the healthcare and pharmaceutical sector. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
Aadi axes 80% of staff after registrational Phase II trial fails
Aadi Biosciences has instituted cash-saving measures after the company decided to halt the registrational Phase II PRECISION1 trial for its…
-
Adcendo and Multitude ink ADC deal potentially worth $1bn
The antibody drug conjugate (ADC) dealmaking trend has seen yet another example as Adcendo has signed a licencing agreement potentially…
-
Phanes acquires second FDA orphan designation for bispecific antibody
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Phanes Therapeutics’ PT217 in neuroendocrine carcinoma…
-
Armed with Phase III win, Incyte eyes label expansion for Monjuvi
Incyte has announced positive topline data from the Phase III inMIND trial evaluating its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in…
-
FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
The US Food and Drug Administration (FDA) has approved Incyte and Syndax Pharmaceuticals’ antibody therapy, Niktimvo (axatilimab-csfr), as a third-line…
-
Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff
Acelyrin has decided to shake up its pipeline; while the company touted positive Phase III data for izokibep in hidradenitis…
-
Syros’ stock craters after Phase II AML trial termination due to inefficacy
Syros Pharmaceuticals has discontinued enrolment in the Phase II SELECT-AML-1 trial evaluating its cancer therapy, tamibarotene, after a futility analysis…
-
FDA rejects Lykos MDMA therapy, asks for another Phase III trial
Lykos Therapeutics’ midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD) has suffered another setback after the US Food and Drug…
-
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial
AN2 Therapeutics has implemented cost-saving measures after “disappointing” topline results from Phase II part of the Phase II/III trial evaluating…